Document 0986
 DOCN  M9540986
 TI    Antiviral and anticancer ribozymes.
 DT    9504
 AU    Poeschla E; Wong-Staal F; Department of Medicine, University of
       California, La Jolla; 92093-0665.
 SO    Curr Opin Oncol. 1994 Nov;6(6):601-6. Unique Identifier : AIDSLINE
       MED/95127799
 AB    Molecular biologists are beginning to apply the site-specific RNase
       properties of ribozymes to gene therapy for HIV infection and cancer.
       Requirements for substrate recognition and cleavage are being finely
       mapped. Methods of augmenting intracellular cleavage and of dissecting
       observed discrepancies between in vitro and cellular activity are being
       explored. Antiviral efficacy against HIV type 1 has been seen in tissue
       culture for both hammerhead and hairpin ribozymes, and a phase I
       clinical trial for ex vivo T-cell gene therapy is planned. Oncogene
       transcripts, such as the bcr/abl fusion messenger RNA and ras, have also
       been targeted with ribozymes.
 DE    Base Sequence  *Gene Therapy  Human  HIV Infections/*THERAPY  Molecular
       Sequence Data  Neoplasms/*THERAPY  RNA, Catalytic/*THERAPEUTIC USE
       Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).